Clinical Trials Using Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-8 of 8
  • Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

    The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.
    Location: 9 locations

  • Guadecitabine and Irinotecan Hydrochloride or Regorafenib or TAS-102 Alone in Treating Patients with Previously Treated Metastatic Colorectal Cancer

    This partially randomized phase I / II trial studies the side effects and best dose of guadecitabine and to see how well it works when given together with irinotecan hydrochloride or regorafenib or trifluridine / tipiracil hydrochloride combination agent TAS-102 (Tas-102) alone in treating patients with previously treated colorectal cancer that has spread to other parts of the body. Guadecitabine, irinotecan hydrochloride, regorafenib, and TAS-102 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

    Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
    Location: 4 locations

  • TAS-102 in Treating Advanced Biliary Tract Cancers

    This phase II trial studies how well trifluridine / tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine / tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Mayo Clinic, Rochester, Minnesota

  • TAS-102 and Yttrium-90 Microsphere Radioembolization in Treating Patients with Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

    This phase I trial studies the side effect and best dose of trifluridine / tipiracil hydrochloride combination agent TAS-102 (TAS-102) and to see how well it works when given together with Yttrium-90 microsphere radioembolization in treating patients with colorectal cancer that has spread to other places in the body and cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine / tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoembolization kills tumor cells by carrying drugs directly into blood vessels near tumors and then blocking the blood flow to allow a higher concentration of the drug to reach the tumor for a longer period of time. Chemoembolization may cause fewer side effects in treating patients with colorectal cancer. Giving trifluridine / tipiracil hydrochloride combination agent TAS-102 and Yttrium-90 microsphere radioembolization may work better in treating patients with colorectal cancer.
    Location: UCSF Medical Center-Parnassus, San Francisco, California

  • TAS-102 and Temozolomide in Treating Patients with Metastatic Neuroendocrine Tumors

    This phase IB trial studies the side effects and best dose of trifluridine / tipiracil hydrochloride combination agent TAS-102 (TAS-102) when given together with temozolomide and to see how well they work in treating patients with neuroendocrine tumors that have spread to other places in the body. Drugs used in chemotherapy, such as TAS-102 and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • Trametinib and TAS-102 in Treating Patients with Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of trametinib and TAS-102 in treating patients with colon or rectal cancer that has spread to other places in the body or cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trametinib and TAS-102 may prevent cancer cells from dividing and work better in treating patients with colon and rectal cancer.
    Location: 7 locations

  • TAS-102 and Radiation Therapy in Treating Patients with Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of trifluridine / tipiracil hydrochloride combination agent TAS-102 (TAS-102) when given together with radiation therapy in treating patients with rectal cancer that has come back, spread to other places in the body, or cannot be removed by surgery. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving TAS-102 with radiation therapy may kill more tumor cells.
    Location: 2 locations